Literature DB >> 17994539

Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients.

Michela Guglieri1, Francesca Magri, Maria Grazia D'Angelo, Alessandro Prelle, Lucia Morandi, Carmelo Rodolico, Rachele Cagliani, Marina Mora, Francesco Fortunato, Andreina Bordoni, Roberto Del Bo, Serena Ghezzi, Serena Pagliarani, Sabrina Lucchiari, Sabrina Salani, Chiara Zecca, Costanza Lamperti, Dario Ronchi, Mohammed Aguennouz, Patrizia Ciscato, Claudia Di Blasi, Alessandra Ruggieri, Isabella Moroni, Anna Turconi, Antonio Toscano, Maurizio Moggio, Nereo Bresolin, Giacomo P Comi.   

Abstract

Limb girdle muscular dystrophies (LGMD) are characterized by genetic and clinical heterogeneity: seven autosomal dominant and 12 autosomal recessive loci have so far been identified. Aims of this study were to evaluate the relative proportion of the different types of LGMD in 181 predominantly Italian LGMD patients (representing 155 independent families), to describe the clinical pattern of the different forms, and to identify possible correlations between genotype, phenotype, and protein expression levels, as prognostic factors. Based on protein data, the majority of probands (n=72) presented calpain-3 deficiency; other defects were as follows: dysferlin (n=31), sarcoglycans (n=32), alpha-dystroglycan (n=4), and caveolin-3 (n=2). Genetic analysis identified 111 different mutations, including 47 novel ones. LGMD relative frequency was as follows: LGMD1C (caveolin-3) 1.3%; LGMD2A (calpain-3) 28.4%; LGMD2B (dysferlin) 18.7%; LGMD2C (gamma-sarcoglycan) 4.5%; LGMD2D (alpha-sarcoglycan) 8.4%; LGMD2E (beta-sarcoglycan) 4.5%; LGMD2F (delta-sarcoglycan) 0.7%; LGMD2I (Fukutin-related protein) 6.4%; and undetermined 27.1%. Compared to Northern European populations, Italian patients are less likely to be affected with LGMD2I. The order of decreasing clinical severity was: sarcoglycanopathy, calpainopathy, dysferlinopathy, and caveolinopathy. LGMD2I patients showed both infantile noncongenital and mild late-onset presentations. Age at disease onset correlated with variability of genotype and protein levels in LGMD2B. Truncating mutations determined earlier onset than missense substitutions (20+/-5.1 years vs. 36.7+/-11.1 years; P=0.0037). Similarly, dysferlin absence was associated with an earlier onset when compared to partial deficiency (20.2+/-standard deviation [SD] 5.2 years vs. 28.4+/-SD 11.2 years; P=0.014). (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17994539     DOI: 10.1002/humu.20642

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  47 in total

1.  Left ventricular deformation abnormalities in a patient with calpainopathy-a case from the three-dimensional speckle-tracking echocardiographic MAGYAR-Path Study.

Authors:  Attila Nemes; Lívia Dézsi; Péter Domsik; Anita Kalapos; Tamás Forster; László Vécsei
Journal:  Quant Imaging Med Surg       Date:  2017-12

2.  Novel diagnostic features of dysferlinopathies.

Authors:  Xiomara Q Rosales; Julie M Gastier-Foster; Sarah Lewis; Malik Vinod; Devon L Thrush; Caroline Astbury; Robert Pyatt; Shalini Reshmi; Zarife Sahenk; Jerry R Mendell
Journal:  Muscle Nerve       Date:  2010-07       Impact factor: 3.217

3.  Low incidence of limb-girdle muscular dystrophy type 2C revealed by a mutation study in Japanese patients clinically diagnosed with DMD.

Authors:  Yo Okizuka; Yasuhiro Takeshima; Kyoko Itoh; Zhujun Zhang; Hiroyuki Awano; Koichi Maruyama; Toshiyuki Kumagai; Mariko Yagi; Masafumi Matsuo
Journal:  BMC Med Genet       Date:  2010-03-30       Impact factor: 2.103

4.  Efficient identification of novel mutations in patients with limb girdle muscular dystrophy.

Authors:  Steven E Boyden; Mustafa A Salih; Anna R Duncan; Alexander J White; Elicia A Estrella; Stephanie L Burgess; Mohammed Z Seidahmed; Abdullah S Al-Jarallah; Hisham M S Alkhalidi; Waleed M Al-Maneea; Richard R Bennett; Salem H Alshemmari; Louis M Kunkel; Peter B Kang
Journal:  Neurogenetics       Date:  2010-07-13       Impact factor: 2.660

5.  Inhibition of proteasome activity promotes the correct localization of disease-causing alpha-sarcoglycan mutants in HEK-293 cells constitutively expressing beta-, gamma-, and delta-sarcoglycan.

Authors:  Stefano Gastaldello; Simona D'Angelo; Susanna Franzoso; Marina Fanin; Corrado Angelini; Romeo Betto; Dorianna Sandonà
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

6.  Dysferlin deficiency treated like refractory polymyositis.

Authors:  Julien Vinit; Maxime Samson; Jean-Baptiste Gaultier; Annie Laquerriere; Elisabeth Ollagnon; Philippe Petiot; Isabelle Marie; Hervé Levesque; Hugues Rousset
Journal:  Clin Rheumatol       Date:  2010-01       Impact factor: 2.980

Review 7.  Therapeutic possibilities in the autosomal recessive limb-girdle muscular dystrophies.

Authors:  Volker Straub; Kate Bushby
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

8.  Phenotypic variability in siblings with calpainopathy (LGMD2A).

Authors:  J Schessl; M C Walter; G Schreiber; U Schara; C R Müller; H Lochmüller; C G Bönnemann; R Korinthenberg; J Kirschner
Journal:  Acta Myol       Date:  2008-10

Review 9.  Caveolinopathies: from the biology of caveolin-3 to human diseases.

Authors:  Elisabetta Gazzerro; Federica Sotgia; Claudio Bruno; Michael P Lisanti; Carlo Minetti
Journal:  Eur J Hum Genet       Date:  2009-07-08       Impact factor: 4.246

10.  New aspects on patients affected by dysferlin deficient muscular dystrophy.

Authors:  Lars Klinge; Ahmed Aboumousa; Michelle Eagle; Judith Hudson; Anna Sarkozy; Gianluca Vita; Richard Charlton; Mark Roberts; Volker Straub; Rita Barresi; Hanns Lochmüller; Kate Bushby
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-06-14       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.